Advertise on podcast: DeviceTalks Podcast Network

Better MedTech requires more than one perspective. In this episode of the DeviceTalks Women in MedTech podcast, Host Kayleen Brown talks with Deanna Harshbarger, CEO of Cala Health, about designing for the whole picture, from patients’ everyday needs to the people, evidence, and business decisions that bring a technology to market. A chemical engineer turned business leader, Harshbarger shares lessons from her career at Johnson & Johnson, Boston Scientific, and Medtronic, including helping build Boston Scientific’s deep brain stimulation franchise and gaining experience with connected devices and direct-to-patient care at Medtronic. Now leading Cala Health, Harshbarger explains how those experiences inform the company’s noninvasive, wrist-worn therapy for action hand tremor in people with essential tremor and Parkinson’s disease. She discusses why clinical effectiveness and usability must go hand in hand, how regulation and reimbursement shape access, and why no single person holds the answer to building a product that works for patients and can scale sustainably. That philosophy also shapes her leadership: removing hurdles, welcoming different perspectives, and ensuring every person knows their voice matters. Kayleen also welcomes Yvonne Bokelman, Executive Director of MedtechWOMEN, for an in-studio conversation about highlights from MedtechVISION 2026, the organization’s growing mentorship and community programs, and why diverse perspectives are essential to better medical device development. Thank you to MedtechWOMEN for sponsoring this episode of the Women in MedTech podcast! To learn more about the organization, please visit: https://medtechwomen.org/ *** Enjoy this podcast? Follow Women in MedTech with Kayleen Brown on all major podcast players: https://women-in-medtech.castos.com/subscribe + Follow us on YouTube.com/@DeviceTalks to ensure you never miss an episode. Want access to the complete DeviceTalks Podcast Network (DTPN)? Follow us today at https://devicetalks.castos.com/subscribe Chapters (00:00:00) - Introduction: Designing for the Whole Picture & Cala Health Milestones(00:03:11) - Interview with In-Studio Guest, Yvonne Bokelman (MedtechWOMEN)(00:16:58) - Start of Keynote Interview with Deanna Harshbarger(00:17:30) - First Job Lessons: From a Bakery to the Chemical Manufacturing Floor(00:22:53) - Finding MedTech: Johnson & Johnson, Cordis & Balanced Regulation(00:30:56) - Boston Scientific: Building Deep Brain Stimulation from the Ground Up(00:39:14) - Medtronic & Connected Health: Serving Patients Directly(00:41:38) - Cala Health: Revolutionizing Tremor Treatment Noninvasively(00:47:13) - From VP to CEO: Scaling Leadership, Team Culture & Mentorship(00:53:58) - Outro: The Whole Picture, MedtechWOMEN & Connected Health Preview

The strongest MedTech innovation doesn't begin with technology in search of an application. It begins with a problem that matters enough to solve. In this episode of the Women in MedTech podcast, Host Kayleen Brown talks with Melaine DiLuzio, Vice President of U.S. Sales for Enabling Technologies within Medtronic’s Cranial & Spinal Technologies (CST) unit, about purposeful innovation—and the responsibility to connect every technology investment to a meaningful clinical need. Melaine shares how more than two decades in MedTech sales, including her progression from associate sales representative to executive leadership, have shaped her approach to purpose, preparation, and building teams that can lead through change. Melaine also unpacks how the CST division approaches enabling technologies: the connected tools for surgical planning, imaging, navigation, robotics, and execution that support cranial and spine procedures. She discusses the importance of designing technology around the realities of clinical workflow, adoption, and long-term utility—and why the most vital question innovators can ask remains: What problem are we solving with this technology? Kayleen also welcomes Caryn Mills, Medical Device Sales Director at HID Global, about how Radio-Frequency Identification (RFID) can support purposeful innovation throughout the medical device lifecycle. Caryn explains how RFID helps OEMs address challenges involving authentication, calibration, traceability, lifecycle management, workflow, and patient safety—and why teams should consider those needs early in the design process. Join us October 22nd and in December to learn more about RFID in two upcoming MDO webinars. Register for free here: https://gateway.on24.com/wcc/experience/elitewtwhmedia/2927718/4415899/medical-design-outsourcing  Thank you to HID Global for supporting this episode of the DeviceTalks Women in MedTech podcast. To learn more about how HID Global works with medical device companies, visit: https://www.hidglobal.com/  *** Enjoy this podcast? Follow Women in MedTech with Kayleen Brown on all major podcast players: https://women-in-medtech.castos.com/subscribe + Follow us on YouTube.com/@DeviceTalks to ensure you never miss an episode. Want access to the complete DeviceTalks Podcast Network (DTPN)? Follow us today at https://devicetalks.castos.com/subscribe Chapters (00:00:00) - Intro: A Note From Kayleen(00:02:00) - In-Studio Guest Caryn Mills, HID Global(00:08:27) - Why RFID Must Be Considered Early in Device Design(00:14:35) - Start of Keynote Interview: Melaine DiLuzio, Medtronic CST(00:15:02) - Purpose in MedTech: The Patient Story That Stays With You(00:31:39) - Why Sales Experience Builds Stronger Leaders(00:37:43) - What Enabling Technologies Make Possible in Cranial & Spine Care(00:39:36) - Stealth AxIS: Connecting Planning, Navigation, Robotics & Data(00:44:16) - Making Technology Adoption Stick: Workflow, ROI & Partnership(00:48:07) - Enabling Technologies and the Move to ASCs

In this episode of DeviceTalks Weekly, Host Tom Salemi talks with Preceptis Medical CEO Dave Carey about his path from MedTech sales to the corner office. Carey shares lessons from launching disruptive technologies at Boston Scientific, Medtronic, Stryker and Pristine Surgical, including what he looks for when hiring salespeople and what it takes to change established clinical workflows. Carey also explains why his new role at Preceptis is personal. After his daughter experienced emergence delirium following anesthesia for an ear tube procedure, Carey was drawn to Hummingbird, Preceptis’ technology for moving ear tube procedures out of the OR and into the physician’s office without general anesthesia. He explains how Preceptis is working with ENTs, pediatricians and parents to drive adoption and why changing even a five-minute procedure requires more than selling a medical device. For more information, visit https://www.hummingbirdeartubes.com  We’ll open the episode with Newmarker’s Newsmakers featuring Mindray, Boston Scientific, Medtronic and Johnson & Johnson MedTech. This episode is sponsored by DeviceTalks Tuesdays Connected Health Series. Register at DeviceTalks.com.  *** Enjoy the show? Follow DeviceTalks Weekly on all major podcast players + Follow us on YouTube.com/@DeviceTalks to ensure you never miss an episode. Want access to the complete DeviceTalks Podcast Network (DTPN)? Follow us today at https://devicetalks.castos.com/subscribe Chapters (00:01:13) - A bit of news from Tom Salemi(00:06:18) - Medtronic hires former Recor CEO to run interventional cardiology group(00:08:15) - Mindray looks to fill hospital ventilator gap left by Philips’ exit(00:09:39) - Medtronic strengthens robotic surgery position with Cornerstone deal, analysts say(00:11:15) - Citi downgrades Boston Scientific as cyberattack recovery compounds competitive pressure(00:14:25) - Johnson & Johnson drops LAA assets following suspended pivotal study(00:17:55) - Keynote Interview: Dave Carey, CEO, Preceptis Medical

In this episode, MassDevice Editor Chris Newmarker interviews Shan Jegatheeswaran, Global President, Polyphonic, Johnson & Johnson MedTech, about what’s to come after the transformation brought to the operating room by digital surgery and robotics. Jegatheeswaran reports that a new wave of surgical intelligence could take that transformation much further by connecting devices, data, AI and clinicians across the entire perioperative pathway. Jegatheeswaran explains why the biggest challenges may no longer be technological. Interoperability, economic incentives, governance, change management and trust all have to evolve alongside AI and connected medical devices. We’ll open the episode with this week’s Newmarker’s Newsmakers – Petal Surgical, Boston Scientific, Medtronic, Zimmer Biomet and Abbott. This episode is sponsored by DeviceTalks West. Go to west.devicetalks.com. *** Enjoy the show? Follow DeviceTalks Weekly on all major podcast players + Follow us on YouTube.com/@DeviceTalks to ensure you never miss an episode. Want access to the complete DeviceTalks Podcast Network (DTPN)? Follow us today at https://devicetalks.castos.com/subscribe Chapters (00:09:55) - Petal Surgical says its first-in-human incisionless surgery is coming soon and offers a first glimpse of its system(00:12:10) - Boston Scientific could miss guidance over cybersecurity incident(00:15:02) - Medtronic veteran joins Teleflex’s board(00:17:14) - Zimmer Biomet lets go of former Nevro CEO amid leadership restructuring(00:19:32) - Abbott earns FDA approval for new dual-energy ablation catheter(00:22:46) - Shan Jegatheeswaran, Global President, Polyphonic, Johnson & Johnson MedTech

In this episode, Host Tom Salemi sits down with Eliane Schutte, CEO of Xeltis, to discuss a remarkable biomaterial designed to help the body grow its own living blood vessels. Schutte explains how the technology is being used for dialysis patients today and how it could eventually transform coronary bypass surgery, peripheral vascular care and even heart valve replacement. In the FOMO studio, Tom speaks with Katie Grant, VP of MR at Siemens Healthineers North America, about the global helium supply and why the MRI industry is working to reduce its reliance on the increasingly precious gas. They explore how new magnet designs could make MRI systems lighter, more accessible and easier to install in new locations. As always, we’ll open the podcast with the top stories from MassDevice in Newmarker’s Newsmakers, delivered by MassDevice Editor Chris Newmarker. This week, Chris covers Medtronic’s major investment in surgical robotics, Enovis’ acquisition of eCential Robotics, Stryker’s move to strengthen its shoulder portfolio, the rebranding of Johnson & Johnson MedTech, and job shifts at Zoll Medical. *** Enjoy the show? Follow DeviceTalks Weekly on all major podcast players + Follow us on YouTube.com/@DeviceTalks to ensure you never miss an episode. Want access to the complete DeviceTalks Podcast Network (DTPN)? Follow us today at https://devicetalks.castos.com/subscribe Chapters (00:04:35) - Zoll Medical is closing a California facility(00:07:33) - Stryker to acquire ZuriMed to boost shoulder offerings(00:09:35) - Enovis to acquire eCential Robotics for €155 million, plans to bring surgical robot to market(00:11:58) - J&J MedTech is rebranding Shockwave Medical(00:14:06) - Medtronic invests $780M in two companies amid Street-beating Q2(00:17:10) - FOMO – The State of Helium in MR – Katie Clark, Siemens Healthineers(00:31:38) - Keynote Interview – Eliane Schutte, CEO, Xeltis

The best leaders do more than set a vision. They know what good looks like—and can help others build toward it. In this episode of the Women in MedTech podcast, Host Kayleen Brown talks with Jaime LaMontagne, Chief Marketing Officer of Astrin Biosciences, about the leadership skills behind effective MedTech marketing. Jaime reflects on her 18 years at Medtronic, where she held a series of marketing and leadership roles across urology, neuromodulation, cardiac rhythm, and perfusion. She shares how that experience—along with her work at Smiths Medical and Exact Sciences—shaped her approach to communication, commercial strategy, and leading through change. Jaime explains why marketers must practice situational leadership: adapting messages for sales teams, physicians, engineers, executives, and patients while grounding every claim in evidence. She also discusses Astrin Biosciences’ work to advance breast cancer detection for women with dense breasts, including the promise behind Certitude, Astrin’s blood-based test in development. As she reflects on moving from large organizations to startup life, Jaime shares the episode’s defining insight: experience gives leaders a clear picture of what good looks like. The work is then to break that vision into practical steps, build the right foundation, and create momentum alongside the people who will bring it to life. *Editors note: This interview was recorded before the Certitude Blood Test launched. Certitude is now available, visit www.certitudetest.com to learn more and follow Certitude test on Facebook or Instagram. Thank you to MedtechWOMEN for sponsoring this episode of the DeviceTalks Women in MedTech podcast, to learn more about MedtechVISION 2026 visit https://medtechwomen.org/. *** Enjoy this podcast? Follow Women in MedTech with Kayleen Brown on all major podcast players: https://women-in-medtech.castos.com/subscribe + Follow us on YouTube.com/@DeviceTalks to ensure you never miss an episode. Want access to the complete DeviceTalks Podcast Network (DTPN)? Follow us today at https://devicetalks.castos.com/subscribe

In this podcast episode, Tito Porras, MD, MBA, CEO and co-founder of startup Inner Logic, shares his unusual path to MedTech entrepreneurship with Host Tom Salemi. Dr. Porras was training to become a neurosurgeon at Johns Hopkins when he began questioning the limits of surgeon training. He realized that even better training wouldn't solve the larger problem: there aren't enough surgeons to provide the care patients need. That realization eventually led Porras to entrepreneurship and Inner Logic, which is developing intelligence and simulation infrastructure that can help develop devices with greater autonomy. Porras explains the difference between automation and autonomy, how AI can help devices perceive and adapt to what's happening during a procedure, and why this technology could eventually expand access to surgical care. Dr. Porras also discusses Inner Logic's work with virtual patients and synthetic data, the potential for autonomy across endovascular, orthopedic and surgical applications, and why the future of autonomous surgery will likely arrive through a series of incremental steps rather than one dramatic leap. MassDevice Editor Chris Newmarker kicks off the podcast with Newmarker's Newsmakers, covering the FDA, Haemonetics, Senseonics, Johnson & Johnson MedTech and Medtronic. *** Enjoy the show? Follow DeviceTalks Weekly on all major podcast players + Follow us on YouTube.com/@DeviceTalks to ensure you never miss an episode. Want access to the complete DeviceTalks Podcast Network (DTPN)? Follow us today at https://devicetalks.castos.com/subscribe Chapters (00:06:15) - Trump nominates policy aide as next FDA commissioner(00:09:28) - Haemonetics reconnects with CSL in US plasma collection deal(00:13:22) - Senseonics sees activist investor take a major stake(00:16:08) - Johnson & Johnson wins FDA clearance for new robotic bronchoscopy software(00:17:45) - Medtronic faces potential injunction in Applied Medical case(00:22:26) - Keynote Interview – Tito Porras, MD, CEO and Co-Founder of Inner Logic

In this episode of DeviceTalks Weekly, Host Tom Salemi welcomes Kendra Grubb, MD, vice president and chief medical officer of Medtronic’s Structural Heart business. Dr. Grubb fulfilled her childhood ambition of becoming a cardiac surgeon and an interventionalist. In this episode, Dr. Grubb discusses how structural heart has transformed over the past two decades and why she believes the field is approaching another major disruption. She explores the future of transcatheter therapies, the growing role of AI, imaging and robotics, the challenge of treating more patients, and how Medtronic is building a broader structural heart portfolio. Dr. Grubb also shares her unusual journey from cardiac surgeon and academic leader to medtech executive and explains why she believes the next generation of structural heart technology must make advanced therapies more accessible to more patients. This episode is sponsored by Cortland Biomedical. Go to https://www.cortlandbiomedical.com/ to see their work in the structural heart space. MassDevice Editor Chris Newmarker delivers this week’s Newmarker’s Newsmakers – Alcon, Intuitive, Cook Medical, CVRx, and GE HealthCare. To register for Medical Design & Outsourcing’s Min-Vasive MedTech Webinar Series, go here: https://gateway.on24.com/wcc/experience/elitewtwhmedia/2927718/4415899/medical-design-outsourcing. *** Enjoy the show? Follow DeviceTalks Weekly on all major podcast players + Follow us on YouTube.com/@DeviceTalks to ensure you never miss an episode. Want access to the complete DeviceTalks Podcast Network (DTPN)? Follow us today at https://devicetalks.castos.com/subscribe

In this episode of the DeviceTalks Weekly podcast, Mobia Medical CEO Richard Foust explains how the “magical” qualities of the company's neurotechnology helped steer it toward an IPO. Mobia Medical’s implantable pulse generator promotes motor skill recovery in patients who have suffered a stroke. The company’s early commercial success has generated modest revenue, but Foust tells host Tom Salemi that “not all revenue is the same,” explaining why a large, untapped and growing market won over venture capital investors a few years ago and public investors this spring. MassDevice Editor Chris Newmarker returns with another edition of Newmarker’s Newsmakers. Tom and Chris repeatedly lament the departure of former Senior Editor Sean Whooley, who recently left MassDevice to pursue other opportunities. Despite his departure, Sean’s reporting remains front and center, as he wrote all five featured stories covering Danaher, Medtronic, Boston Scientific, Integer, Teleflex, and private equity investors. Special thanks to our sponsors of MassDevice’s Diabetes Technology Innovations Special Report: Cadence, Jabil, and Viant Medical! Download the complimentary report here: https://www.massdevice.com/diabetes-technology-innovations-special-report-2026/ *** Enjoy the show? Follow DeviceTalks Weekly on all major podcast players + Follow us on YouTube.com/@DeviceTalks to ensure you never miss an episode. Want access to the complete DeviceTalks Podcast Network (DTPN)? Follow us today at https://devicetalks.castos.com/subscribe

In this episode of the DeviceTalks Weekly podcast, we tackle a range of topics related to the surgical robotics industry. In our keynote conversation, Brian Miller, formerly of Intuitive and now CEO of Sovato, discusses the potential of telesurgery, a promising capability of surgical robotic systems that could save lives while reducing costs and improving efficiency across the healthcare system. In our FOMO interview, Christy Gaudet, global head of solutions at Karl Storz, explains the company's decision to discontinue the Asensus Surgical robotics systems and focus on the often under-appreciated art of imaging. Finally, surgical robotics expert Steve Bell shares his top five newsmakers from the Society of Robotic Surgery (SRS) Annual Meeting, including Ottava, AI, and humanoid surgical robots. Host Tom Salemi also interviews Jim Leonard, vice president of sales at Harmonic Drive, the sponsor of this episode. Visit http://HarmonicDrive.net for more information. *** Enjoy the show? Follow DeviceTalks Weekly on all major podcast players + Follow us on YouTube.com/@DeviceTalks to ensure you never miss an episode. Want access to the complete DeviceTalks Podcast Network (DTPN)? Follow us today at https://devicetalks.castos.com/subscribe

In this episode of the DeviceTalks Weekly Podcast, Host Tom Salemi is joined by Harith Rajagopalan, MD, PhD, co-founder and CEO of Fractyl Health. Dr. Rajagopalan explains why Fractyl shifted its focus from treating type 2 diabetes to helping former GLP-1 users maintain their weight loss with Revita, an outpatient endoscopic procedure designed to target the root causes of metabolic disease in the duodenum. He also shares new clinical data, the strategy behind Fractyl's pivotal trial, the company's commercialization plans, and why he believes metabolic endoscopy could become an entirely new category of care. This episode is brought to you by the  DeviceTalks Interventional Innovations series, July 28-30th. To register for this complimentary series, click here. *** Enjoy the show? Follow DeviceTalks Weekly on all major podcast players + Follow us on YouTube.com/@DeviceTalks to ensure you never miss an episode. Want access to the complete DeviceTalks Podcast Network (DTPN)? Follow us today at https://devicetalks.castos.com/subscribe Chapters (00:01:35) - Keynote Interview - Harith Rajagopalan, MD, PhD, Co-Founder and Chief Executive Officer, Fractyl Health(00:06:26) - Starting with Back of the Napkin Idea(00:18:45) - Why patients are enthusiastic(00:24:35) - The Parallels to Renal Denervation(00:29:40) - Commercial Plans, Pivotal Trials & What's Next

In this episode of the DeviceTalks Weekly Podcast, Managing Editor Kayleen Brown sits down with Johnson & Johnson MedTech Heart Recovery Worldwide President Devi Govender at DeviceTalks Boston. Govender shares how a deeply personal family experience shaped her mission to transform cardiovascular care. She reflects on Abiomed's integration into Johnson & Johnson, the evolution of heart recovery therapies, and why the industry must shift its mindset from treating "heart failure" to enabling "heart recovery." The discussion explores patient-centered innovation, AI, clinical evidence, and the power of combining technologies, data, and advocacy to redefine the future of cardiovascular care for patients around the world. This episode is sponsored by  Freudenberg Medical. Listen for a conversation with Shane Healy, Senior Director of Technology. Visit FreudenbergMedical.com for more information. We'll kick off this episode with Newmarker's Newsmakers. Host Tom Salemi and MassDevice Editor Chris Newmarker revisit the top MedTech stories of the week: Zeta Surgical, Hologic, Medtronic, Fractyl Health, and Vicarious Surgical. --- Enjoy the show? Follow DeviceTalks Weekly on all major podcast platforms, and subscribe to YouTube.com/@DeviceTalks so you never miss an episode. Want access to the complete DeviceTalks Podcast Network (DTPN)? Subscribe today at [https://devicetalks.castos.com/subscribe](https://devicetalks.castos.com/subscribe). Chapters (00:09:10) - Zeta wins FDA clearance for TMS robotic stereotactic system(00:13:01) - Private equity firms reportedly set $4B price on Hologic Surgical unit(00:15:03) - Medtronic, FDA pick up legal victories in spinal cord stimulator suits(00:16:20) - Fractyl Health says its single-catheter treatment maintained most GLP-1 weight loss(00:22:17) - Vicarious Surgical's board wants to shut down and liquidate the robotics developer(00:29:53) - Interview with Shane Healy, Senior Director of Technology, Freudenberg Medical(00:36:53) - Keynote interview with Devi Govender, Worldwide President, Heart Recovery, Johnson & Johnson MedTech

In this episode of DeviceTalks Weekly, Host Tom Salemi explores the breakthrough technologies—and the unique culture—driving one of MedTech's most ambitious missions with XCATH CEO Eduardo Fonseca. Fonseca shares the remarkable story behind XCATH's first remote robotic stroke procedure. Fonseca recounts the years of preparation, the high-stakes operation, and the emotional moment when a patient facing severe disability walked away with what he calls "a second birthday." Along the way, Tom and Eduardo discuss AI's growing role in surgery, the global shortage of stroke specialists, the future of robotic intervention, and why expanding access—not simply advancing technology—is the company's ultimate goal. To learn more about XCATH and talk with Fonseca, join us on July 29 for a live DeviceTalks discussion. Register here for the free webinar. Thank you to our sponsors Confluent, Jabil, Maxon, Solesis, Viant, and VitalPath. MassDevice Editor Chris Newmarker returns to deliver this episode’s Newmarker’s Newsmakers – MDUFA, Corza Medical, Resmed, GTCR, Zimmer Biomet, Pacira Biosciences, and Johnson & Johnson MedTech.  *** Enjoy the show? Follow DeviceTalks Weekly on all major podcast players + Follow us on YouTube.com/@DeviceTalks to ensure you never miss an episode. Want access to the complete DeviceTalks Podcast Network (DTPN)? Follow us today at https://devicetalks.castos.com/subscribe Chapters (00:08:36) - FDA releases draft MDUFA VI agreement outlining proposed legislation and program changes(00:12:50) - Resmed to sell MatrixCare software business to private equity firm for $490M/ GTCR to divest Biosurgery unit of Corza Medical(00:15:58) - Medtronic’s chief sustainability officer is departing(00:17:55) - Zimmer Biomet to pay up to $140M for Iovera nerve therapy tech from Pacira BioSciences(00:19:56) - Johnson & Johnson wins FDA approval for ThermoCool SmartTouch dual-energy ablation system

In this episode of the DeviceTalks Weekly Podcast, host Tom Salemi is reassured by his conversation with Joe Catanese, CEO of Calyxo, a urology startup that has developed a system designed to simplify kidney stone removal. Catanese previously helped build Neotract, a urology startup that was acquired by Teleflex for more than $1 billion. Now, he's leading another potential gamechanger and may have his sights set on an IPO. Speaking of gamechangers, HistoSonics continues to shatter fundraising expectations. The company recently completed a financing round that valued it at $3.75 billion. In this week's FOMO interview, HistoSonics President and CEO Mike Blue speaks with MassDevice Editor Chris Newmarker during a keynote conversation at DeviceTalks Minnesota. In this excerpt, Blue reflects on the company's first major fundraising round, which attracted high-profile investors including Jeff Bezos and Peter Thiel, and shares his perspective on just how large the opportunity for histotripsy could become. But first, Tom and Jim Hammerand, managing editor of Medical Design & Outsourcing, discuss AI—or LLMs, or whatever term you prefer. Is the hype beginning to fade? And what should the industry make of the recent announcement from Midjourney Medical? *** Enjoy the show? Follow DeviceTalks Weekly on all major podcast players + Follow us on YouTube.com/@DeviceTalks to ensure you never miss an episode. Want access to the complete DeviceTalks Podcast Network (DTPN)? Follow us today at https://devicetalks.castos.com/subscribe Chapters (00:05:29) - AI Talk with Jim Hammerand, managing editor, Medical Design & Outsourcing(00:24:46) - DeviceTalks Minnesota interview excerpt - Mike Blue, CEO and President, Histosonics(00:41:44) - Keynote Interview with Joe Catanese, CEO and President, Calyxo

In this episode of the DeviceTalks Weekly Podcast, Host Tom Salemi visits his MedTech happy place — renal denervation — with Recor Medical COO Helen Reeve Stoffer. Reeve Stoffer joined the company shortly before the bottom fell out of the renal denervation market in 2014. This interview picks up from that point and follows Recor's pursuit of FDA approval to where denervation technology may be applied next. This week’s FOMO features a portion of a keynote interview with Manny Villafaña, MedTech legend and CEO of Medical 21. The conversation took place at DeviceTalks Minnesota and focuses on the dream that saved St. Jude Medical. Skyler Rivera, associate editor of MassDevice, gives us a preview of her upcoming feature in Medical Design & Outsourcing magazine on the race to provide telesurgery capabilities to surgical robotic systems. *** Enjoy the show? Follow DeviceTalks Weekly on all major podcast players + Follow us on YouTube.com/@DeviceTalks to ensure you never miss an episode. Want access to the complete DeviceTalks Podcast Network (DTPN)? Follow us today at https://devicetalks.castos.com/subscribe Chapters (00:02:42) - Associate Editor Skyler Rivera's path the MedTech (and MassDevice)(00:06:00) - MDO covers the race for robotic telesurgery platforms in stroke(00:11:12) - Rivera reviews the race leaders(00:16:30) - FOMO Studio - Manny Villafana, MedTech Legend and CEO of Medical 21(00:28:19) - Keynote Interview - Helen Reeve Stoffer, COO, Recor Medical